Novartis wraps first phase of Alcon buyout

Novartis completed the first stage of its $38 billion takeover of the U.S. eye care company Alcon, paying Nestle $10.4 billion in cash for a 25 percent stake in the company, some $200 million less than the originally announced price. Novartis retains exclusive rights to buy Nestle's remaining 52 percent share. Report

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.